Qaytona is free while it's in beta — Get started

Ingredients

Vitex (Chaste Tree)

Vitex agnus-castus · Chasteberry · Chaste tree berry · Agnus castus

Snapshot

IndicationsContraindications
  • Premenstrual syndrome1, 2
  • Premenstrual dysphoric disorder3
  • Cyclic breast pain4, 5
  • Mild hyperprolactinemia6
  • Menstrual cycle irregularity5, 7, 8
  • Menopausal symptoms9
  • Pregnancy10
  • Breastfeeding10
  • Hormone-sensitive cancers9

Vitex (chasteberry), the fruit extract of Vitex agnus-castus, is a Mediterranean and Central Asian shrub used traditionally for gynecological complaints9. Its fruit diterpenes interact with dopamine D2 receptors, lowering prolactin release6. Supplementation follows from that effect: premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are the most studied uses, followed by cyclic breast pain, mild hyperprolactinemia, menstrual irregularity, and menopausal symptoms, where trials are few. Reproductive-age women with cyclical symptoms are the typical users.

Meta-analyses of placebo-controlled trials favor Vitex extracts for PMS, though high risk of bias, heterogeneity, and publication bias limit certainty1, 2. Systematic reviews also report benefit for cyclic breast pain11, 12. In PMDD, one trial found Vitex equivalent to fluoxetine while another favored fluoxetine13. A 2023 review of small studies and case series proposed a role in mild hyperprolactinemia, and no large randomized trial has tested it6. Products are standardized fruit extracts in tablets or capsules, as well as liquid tinctures and whole-herb powders; see Form comparison. Quality varies, and some supplements lack marker compounds14.

Pregnancy and lactation are the most consequential exclusions, since Vitex acts on prolactin and hormone signaling15. Health Canada labels ask for a practitioner's advice before use with hormone-containing medications such as oral contraceptives10. Dopamine antagonists are a theoretical interaction15.

Last updated October 16, 2026. Read how we make monographs.

In the full monograph

61 sources, 49 studies

  • When to useThe situations practitioners use it for, each with the reason and the study behind it.
  • SafetyWho should avoid it, who needs extra care, and the side effects reported in studies.
  • InteractionsThe medicines and supplements it interacts with, the effect of each, and what labeling says to watch.
  • Protocol notesThe doses used in studies, how and when they were taken, and how the forms on the market compare.
  • How it worksWhat it is and how it works in the body, in plain terms.
  • Published studiesThe studies behind each use, popular claims checked against them, and trials still under way.
  • Word of mouthWhat patients and practitioners report online, kept separate from the clinical evidence.
  • Clinical perspectiveA closing read of where the evidence is solid, where it is thin, and what has not been studied.

Sources

  1. 1The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis.pubmed.ncbi.nlm.nih.govVerkaik, Kamperman, van Westrhenen et al. · American journal of obstetrics and gynecology · 2017 · Pubmed
  2. 2Vitex agnus-castus in premenstrual syndrome: A meta-analysis of double-blind randomised controlled trials.pubmed.ncbi.nlm.nih.govCsupor, Lantos, Hegyi et al. · Complementary therapies in medicine · 2019 · Pubmed
  3. 3Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review.pubmed.ncbi.nlm.nih.govCerqueira, Frey, Leclerc et al. · Archives of women's mental health · 2017 · Pubmed
  4. 4[Treatment of cyclical mastodynia using an extract of Vitex agnus castus: results of a double-blind comparison with a placebo].pubmed.ncbi.nlm.nih.govHalaska, Raus, Bĕles et al. · Ceska gynekologie · 1998 · Pubmed
  5. 5Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study.pubmed.ncbi.nlm.nih.govHöller, Steindl, Abramov-Sommariva et al. · Archives of gynecology and obstetrics · 2024 · Pubmed
  6. 6Vitex agnus castus effects on hyperprolactinaemia.pubmed.ncbi.nlm.nih.govPuglia, Lowry, Tamagno · Frontiers in endocrinology · 2023 · Pubmed
  7. 7Case Series: Real-Life Experience with Vitex Agnus-Castus Extract Ze 440 Medication in Adolescents.pubmed.ncbi.nlm.nih.govErkert · Complementary medicine research · 2026 · Pubmed
  8. 8Herbal Medicine for Oligomenorrhea and Amenorrhea: A Systematic Review of Ancient and Conventional Medicine.pubmed.ncbi.nlm.nih.govMoini Jazani, Hamdi, Tansaz et al. · BioMed research international · 2018 · Pubmed
  9. 9NCCIHnccih.nih.govNational Center for Complementary and Integrative Health
  10. 10Health Canadahealth-products.canada.caLabel statements and adult daily amounts Health Canada authorized on licensed natural health products with this ingredient alone, from the Licensed Natural Health Products Database. Contains information licensed under the Open Government Licence – Canada
  11. 11The Effectiveness of Herbal Medicines on Cyclic Mastalgia: A Systematic Review on Meta-analysis.pubmed.ncbi.nlm.nih.govMirzaee, Fakari, Babakhanian et al. · Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2022 · Pubmed
  12. 12Can Vitex Agnus Castus be Used for the Treatment of Mastalgia? What is the Current Evidence?pubmed.ncbi.nlm.nih.govCarmichael · Evidence-based complementary and alternative medicine : eCAM · 2008 · Pubmed
  13. 13Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials.pubmed.ncbi.nlm.nih.govvan Die, Burger, Teede et al. · Planta medica · 2013 · Pubmed
  14. 14Quality Assessment of Medicinal Product and Dietary Supplements Containing Vitex agnus-castus by HPLC Fingerprint and Quantitative Analyses.pubmed.ncbi.nlm.nih.govSogame, Naraki, Sasaki et al. · Chemical & pharmaceutical bulletin · 2019 · Pubmed
  15. 15Vitex agnus castus: a systematic review of adverse events.pubmed.ncbi.nlm.nih.govDaniele, Thompson Coon, Pittler et al. · Drug safety · 2005 · Pubmed